vs

Side-by-side financial comparison of MARCUS CORP (MCS) and PTC THERAPEUTICS, INC. (PTCT). Click either name above to swap in a different company.

MARCUS CORP is the larger business by last-quarter revenue ($193.5M vs $164.7M, roughly 1.2× PTC THERAPEUTICS, INC.). On growth, MARCUS CORP posted the faster year-over-year revenue change (2.8% vs -22.7%). MARCUS CORP produced more free cash flow last quarter ($26.4M vs $-36.6M). Over the past eight quarters, MARCUS CORP's revenue compounded faster (18.2% CAGR vs -11.5%).

Marcus & Millichap, Inc. is an American company that provides real estate brokerage, mortgage brokerage, research, and advisory services in the U.S. and Canada in the field of commercial property. It popularized the practice of listing properties exclusively with one brokerage firm. The company has over 1,800 employees in more than 80 offices across the U.S. and Canada.

PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.

MCS vs PTCT — Head-to-Head

Bigger by revenue
MCS
MCS
1.2× larger
MCS
$193.5M
$164.7M
PTCT
Growing faster (revenue YoY)
MCS
MCS
+25.5% gap
MCS
2.8%
-22.7%
PTCT
More free cash flow
MCS
MCS
$63.0M more FCF
MCS
$26.4M
$-36.6M
PTCT
Faster 2-yr revenue CAGR
MCS
MCS
Annualised
MCS
18.2%
-11.5%
PTCT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MCS
MCS
PTCT
PTCT
Revenue
$193.5M
$164.7M
Net Profit
$-135.0M
Gross Margin
Operating Margin
0.9%
-43.3%
Net Margin
-82.0%
Revenue YoY
2.8%
-22.7%
Net Profit YoY
-104.8%
EPS (diluted)
$-1.63

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MCS
MCS
PTCT
PTCT
Q4 25
$193.5M
$164.7M
Q3 25
$210.2M
$211.0M
Q2 25
$206.0M
$178.9M
Q1 25
$148.8M
$1.2B
Q4 24
$188.3M
$213.2M
Q3 24
$232.7M
$196.8M
Q2 24
$176.0M
$186.7M
Q1 24
$138.5M
$210.1M
Net Profit
MCS
MCS
PTCT
PTCT
Q4 25
$-135.0M
Q3 25
$16.2M
$15.9M
Q2 25
$7.3M
$-64.8M
Q1 25
$-16.8M
$866.6M
Q4 24
$986.0K
$-65.9M
Q3 24
$23.3M
$-106.7M
Q2 24
$-20.2M
$-99.2M
Q1 24
$-11.9M
$-91.6M
Operating Margin
MCS
MCS
PTCT
PTCT
Q4 25
0.9%
-43.3%
Q3 25
10.8%
1.4%
Q2 25
6.3%
-19.5%
Q1 25
-13.7%
82.5%
Q4 24
-1.2%
-76.2%
Q3 24
14.1%
-27.7%
Q2 24
1.3%
-21.5%
Q1 24
-12.0%
-21.6%
Net Margin
MCS
MCS
PTCT
PTCT
Q4 25
-82.0%
Q3 25
7.7%
7.5%
Q2 25
3.6%
-36.3%
Q1 25
-11.3%
73.7%
Q4 24
0.5%
-30.9%
Q3 24
10.0%
-54.2%
Q2 24
-11.5%
-53.1%
Q1 24
-8.6%
-43.6%
EPS (diluted)
MCS
MCS
PTCT
PTCT
Q4 25
$-1.63
Q3 25
$0.20
Q2 25
$-0.83
Q1 25
$10.04
Q4 24
$-0.85
Q3 24
$-1.39
Q2 24
$-1.29
Q1 24
$-1.20

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MCS
MCS
PTCT
PTCT
Cash + ST InvestmentsLiquidity on hand
$23.4M
$1.9B
Total DebtLower is stronger
$159.0M
Stockholders' EquityBook value
$457.4M
$-205.3M
Total Assets
$1.0B
$2.9B
Debt / EquityLower = less leverage
0.35×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MCS
MCS
PTCT
PTCT
Q4 25
$23.4M
$1.9B
Q3 25
$7.4M
$1.7B
Q2 25
$14.9M
$2.0B
Q1 25
$11.9M
$2.0B
Q4 24
$40.8M
$1.1B
Q3 24
$28.4M
$1.0B
Q2 24
$32.8M
$1.1B
Q1 24
$17.3M
$884.8M
Total Debt
MCS
MCS
PTCT
PTCT
Q4 25
$159.0M
Q3 25
$162.0M
Q2 25
$179.9M
Q1 25
$198.9M
Q4 24
$159.1M
Q3 24
$173.1M
Q2 24
$175.7M
Q1 24
$169.8M
Stockholders' Equity
MCS
MCS
PTCT
PTCT
Q4 25
$457.4M
$-205.3M
Q3 25
$454.3M
$-155.8M
Q2 25
$448.4M
$-206.5M
Q1 25
$441.8M
$-185.8M
Q4 24
$464.9M
$-1.1B
Q3 24
$462.3M
$-1.1B
Q2 24
$449.4M
$-980.2M
Q1 24
$459.3M
$-893.9M
Total Assets
MCS
MCS
PTCT
PTCT
Q4 25
$1.0B
$2.9B
Q3 25
$1.0B
$2.6B
Q2 25
$1.0B
$2.6B
Q1 25
$1.0B
$2.7B
Q4 24
$1.0B
$1.7B
Q3 24
$1.0B
$1.8B
Q2 24
$1.1B
$1.9B
Q1 24
$1.0B
$1.8B
Debt / Equity
MCS
MCS
PTCT
PTCT
Q4 25
0.35×
Q3 25
0.36×
Q2 25
0.40×
Q1 25
0.45×
Q4 24
0.34×
Q3 24
0.37×
Q2 24
0.39×
Q1 24
0.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MCS
MCS
PTCT
PTCT
Operating Cash FlowLast quarter
$48.8M
$-34.3M
Free Cash FlowOCF − Capex
$26.4M
$-36.6M
FCF MarginFCF / Revenue
13.6%
-22.3%
Capex IntensityCapex / Revenue
11.6%
1.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$989.0K
$702.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MCS
MCS
PTCT
PTCT
Q4 25
$48.8M
$-34.3M
Q3 25
$39.1M
$-66.3M
Q2 25
$31.6M
$-58.3M
Q1 25
$-35.3M
$870.1M
Q4 24
$52.6M
$-30.0M
Q3 24
$30.5M
$-77.0M
Q2 24
$36.0M
$-71.5M
Q1 24
$-15.1M
$70.8M
Free Cash Flow
MCS
MCS
PTCT
PTCT
Q4 25
$26.4M
$-36.6M
Q3 25
$18.2M
$-69.7M
Q2 25
$14.7M
$-59.6M
Q1 25
$-58.3M
$868.4M
Q4 24
$27.1M
$-33.8M
Q3 24
$12.0M
$-77.5M
Q2 24
$16.1M
$-78.8M
Q1 24
$-30.5M
$61.2M
FCF Margin
MCS
MCS
PTCT
PTCT
Q4 25
13.6%
-22.3%
Q3 25
8.7%
-33.1%
Q2 25
7.1%
-33.3%
Q1 25
-39.2%
73.8%
Q4 24
14.4%
-15.8%
Q3 24
5.2%
-39.4%
Q2 24
9.2%
-42.2%
Q1 24
-22.0%
29.1%
Capex Intensity
MCS
MCS
PTCT
PTCT
Q4 25
11.6%
1.4%
Q3 25
9.9%
1.6%
Q2 25
8.2%
0.7%
Q1 25
15.5%
0.1%
Q4 24
13.5%
1.8%
Q3 24
7.9%
0.3%
Q2 24
11.3%
4.0%
Q1 24
11.1%
4.6%
Cash Conversion
MCS
MCS
PTCT
PTCT
Q4 25
Q3 25
2.41×
-4.17×
Q2 25
4.32×
Q1 25
1.00×
Q4 24
53.31×
Q3 24
1.31×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MCS
MCS

Theatres$123.1M64%
Concessions$51.0M26%
Food And Beverage$21.2M11%

PTCT
PTCT

Segment breakdown not available.

Related Comparisons